# A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)

> **NCT01984697** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1518 (actual)

## Conditions studied

- Human Papillomavirus Infection

## Interventions

- **BIOLOGICAL:** V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)

## Key facts

- **NCT ID:** NCT01984697
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-12
- **Primary completion:** 2015-06-19
- **Final completion:** 2017-07-24
- **Target enrollment:** 1518 (ACTUAL)
- **Last updated:** 2018-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01984697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01984697, "A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01984697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*